Organization (Hospital)
Tel Aviv Sourasky Medical Center
ClinicalTrials.gov lists Tel Aviv Sourasky Medical Center as lead sponsor of 552 trials. It has 31 active development programs and 93 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 7 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 11 in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Tel Aviv Sourasky Medical Center: 552 lead-sponsored trials and 1 legal-entity registration.
Disease areas (329)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 37 |
| Parkinson Disease | 28 |
| Inflammatory Bowel Diseases | 23 |
| Obesity | 19 |
| Diabetes Mellitus | 15 |
Showing 5 of 329 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 18 |
| 2024 | 11 |
| 2023 | 10 |
| 2022 | 13 |
| 2021 | 22 |
| 2020 | 44 |
| 2019 | 31 |
| 2018 | 35 |
| 2017 | 26 |
Showing 10 of 25 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 25 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 101 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (31)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells. | Lymphoma, Non-Hodgkin | Phase 2 | 1 |
| Ixazomib/Pomalidomide/Dexamethasone | Multiple Myeloma | Phase 2 | 1 |
| Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells. | Lymphoma | Phase 2 | 1 |
| Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells. | Lymphoma, Follicular | Phase 2 | 1 |
| Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor) | Ovarian Neoplasms | Phase 2 | 1 |
Showing 5 of 31 active programs.
Approved assets (93)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| (R,S)-ketamine (Pilot I) | 7 |
| MORPHINE | 4 |
| Lidocaine | 3 |
| Tocilizumab | 2 |
| INFLUENZA VACCINE | 2 |
Showing 5 of 93 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 45% hit target (n=33) | 59% on time (n=34) |
Journals published in (478)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Cochrane database of systematic reviews | 16 |
| The New England journal of medicine | 16 |
| British journal of anaesthesia | 9 |
| Diabetes care | 9 |
| Anesthesia and analgesia | 8 |
Showing 5 of 478 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 0 | 2009-02-03 |
Organization relationships (61)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Hadassah Medical Organization | Co sponsors trial with | 6 |
| Soroka University Medical Center | Co sponsors trial with | 6 |
| KU Leuven | Co sponsors trial with | 5 |
| Schneider Children's Medical Center, Israel | Co sponsors trial with | 4 |
| Rebecca Sieff Hospital | Co sponsors trial with | 4 |
Showing 5 of 61 relationships.
Latest dated events (606)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 606 events.
Biomarker capability evidence (292)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGA | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 292 evidence rows.
Biomarkers this organization publishes on (430)
Shown in this order: most publications first.
Showing 5 of 430 biomarkers.
On Scientist.com
Tel Aviv Sourasky Medical Center is listed as a research supplier in the Scientist.com network.
Service areas
Tel-Aviv Souraski Medical Center offers in vitro human systems, in vivo small animal research systems, and translational research services.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Tel Aviv Sourasky Medical Center on Scientist.com
For prices, more details, or to contact Tel Aviv Sourasky Medical Center, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.